SMTL ID : 8tzh.1

Structure of full-length LRRK2 bound to MLi-2 (I2020T mutant)

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

hetero-1-1-mer

Ligands

1 x A1N: (2~{R},6~{S})-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1~{H}-indazol-3-yl]pyrimidin-4-yl]morpholine(Non-covalent)

A1N.1: 14 residues within 4Å: Chain B: L.1885, G.1886, D.1887, V.1893, R.1895, M.1947, E.1948, L.1949, A.1950, G.1953, S.1954, H.1998, L.2001, A.2016 7 PLIP interactions: 7 interactions with chain B Hydrophobic interactions: B:L.1885, B:L.1949, B:L.2001, B:L.2001, B:A.2016 Hydrogen bonds: B:E.1948, B:A.1950

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Covalent)

GDP.2: 11 residues within 4Å: Chain B: G.1344, S.1345, G.1346, K.1347, T.1348, T.1349, T.1368, T.1452, H.1453, N.1489, A.1490 9 PLIP interactions: 9 interactions with chain B Hydrogen bonds: B:G.1344, B:S.1345, B:K.1347, B:T.1348, B:T.1349, B:T.1368 Salt bridges: B:K.1347 pi-Stacking: B:H.1453 pi-Cation interactions: B:H.1453

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Sanz Murillo, M. et al., Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Sci Adv (2023)

Release Date

2023-12-06

Peptides

E11 DARPin: A
Leucine-rich repeat serine/threonine-protein kinase 2: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

B
A

E11 DARPin

Leucine-rich repeat serine/threonine-protein kinase 2

Related Entries With Identical Sequence